Investors - Press Releases
TRHC's Clinical Advisory Panel Meeting Provides Insights on PACE Pharmacy
The sessions focused on topics such as strategies for deprescribing opioids among the elderly; research supporting pharmacogenomics, which considers how responses to drugs differ based on an individual's genes; and how implementing interventions that promote the safe use of medications could lead to significant cost savings for PACE programs.
"TRHC's CAP Meeting provides an opportunity to bring together medical directors from some of the leading PACE programs in the country to share insights and learn about findings from PACE-related research," said
A prominent theme of this year's CAP Meeting was personalized and precision pharmacotherapy, with presentations highlighting how pharmacogenomics can bolster the safe use of medications. TRHC offers pharmacogenomic analysis from clinical pharmacists through the medication risk mitigation services its
"With personalized and precision pharmacotherapy, new and expanding PACE programs can risk stratify and reduce harmful and avoidable adverse drug events among participants," said
TRHC's MedWise® Science identifies simultaneous multi-drug interactions and helps pharmacists make recommendations to PACE prescribers, playing a key role in advanced pharmacotherapy, which was highlighted at the CAP Meeting. TRHC's MedWise Matrix, which applies MedWise Science and provides a detailed look at potential simultaneous multi-drug interactions, can incorporate pharmacogenomic data, offering a deeper review of drug regimens among PACE participants.
View original content to download multimedia:https://www.prnewswire.com/news-releases/trhcs-clinical-advisory-panel-meeting-provides-insights-on-pace-pharmacy-301628906.html
TRHC Media Contact: Anthony Mirenda, firstname.lastname@example.org, 908-380-2143; TRHC Investors: Frank Sparacino, email@example.com, 866.648.2767